Acknowledgement
Supported by : British Heart Foundation, NovoNordisk Foundation
References
- Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77. https://doi.org/10.1161/01.CIR.67.5.968
- Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115 Suppl 8A:37S-41S. https://doi.org/10.1016/j.amjmed.2003.08.012
- Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013;62:921-5. https://doi.org/10.1016/j.jacc.2013.06.027
- Greif M, Becker A, von Ziegler F, et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:781-6. https://doi.org/10.1161/ATVBAHA.108.180653
- McQuaid SE, Humphreys SM, Hodson L, Fielding BA, Karpe F, Frayn KN. Femoral adipose tissue may accumulate the fat that has been recycled as VLDL and nonesterified fatty acids. Diabetes 2010;59:2465-73. https://doi.org/10.2337/db10-0678
- Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO Expert Consultation on Waist Circumference and Waist-Hip Ratio. Eur J Clin Nutr 2010;64:2-5. https://doi.org/10.1038/ejcn.2009.139
- Nagarajan V, Kohan L, Holland E, Keeley EC, Mazimba S. Obesity paradox in heart failure: a heavy matter. ESC Heart Fail 2016;3:227-34. https://doi.org/10.1002/ehf2.12120
- Park J, Ahmadi SF, Streja E, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014;56:415-25. https://doi.org/10.1016/j.pcad.2013.10.005
- Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes Rev 2016;17:989-1000. https://doi.org/10.1111/obr.12440
- Akoumianakis I, Tarun A, Antoniades C. Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. Br J Pharmacol 2016 [Epub ahead of print].
- Fuster JJ, Ouchi N, Gokce N, Walsh K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ Res 2016;118:1786-807. https://doi.org/10.1161/CIRCRESAHA.115.306885
- Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006;64:355-65.
- Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. Gerontology 2012;58:15-23. https://doi.org/10.1159/000321319
- Hassan M, Latif N, Yacoub M. Adipose tissue: friend or foe? Nat Rev Cardiol 2012;9:689-702. https://doi.org/10.1038/nrcardio.2012.148
- Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 2015;132:1639-47. https://doi.org/10.1161/CIRCULATIONAHA.114.015000
- Marinou K, Hodson L, Vasan SK, et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 2014;37:821-9. https://doi.org/10.2337/dc13-1353
- Jo J, Gavrilova O, Pack S, et al. Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth. PLOS Comput Biol 2009;5:e1000324. https://doi.org/10.1371/journal.pcbi.1000324
- Laforest S, Labrecque J, Michaud A, Cianflone K, Tchernof A. Adipocyte size as a determinant of metabolic disease and adipose tissue dysfunction. Crit Rev Clin Lab Sci 2015;52:301-13. https://doi.org/10.3109/10408363.2015.1041582
- Tanaka N, Takahashi S, Matsubara T, et al. Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice. J Biol Chem 2015;290:3092-105. https://doi.org/10.1074/jbc.M114.605980
- Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004;84:277-359. https://doi.org/10.1152/physrev.00015.2003
- Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol 2014;10:24-36. https://doi.org/10.1038/nrendo.2013.204
- Tam CS, Lecoultre V, Ravussin E. Brown adipose tissue: mechanisms and potential therapeutic targets. Circulation 2012;125:2782-91. https://doi.org/10.1161/CIRCULATIONAHA.111.042929
- Villarroya J, Cereijo R, Villarroya F. An endocrine role for brown adipose tissue? Am J Physiol Endocrinol Metab 2013;305:E567-72. https://doi.org/10.1152/ajpendo.00250.2013
- Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med 2013;19:1252-63. https://doi.org/10.1038/nm.3361
- Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest 2017;127:74-82. https://doi.org/10.1172/JCI88883
- Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-8. https://doi.org/10.1172/JCI20514
- Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11-8. https://doi.org/10.1111/j.1467-789X.2009.00623.x
- Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-39. https://doi.org/10.1016/j.mce.2009.08.018
- Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost 2015;113:553-66. https://doi.org/10.1160/TH14-06-0513
- Margaritis M, Antonopoulos AS, Digby J, et al. Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 2013;127:2209-21. https://doi.org/10.1161/CIRCULATIONAHA.112.001133
- Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R, Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol 2012;165:670-82. https://doi.org/10.1111/j.1476-5381.2011.01479.x
- Mazurek T, Opolski G. Pericoronary adipose tissue: a novel therapeutic target in obesity-related coronary atherosclerosis. J Am Coll Nutr 2015;34:244-54. https://doi.org/10.1080/07315724.2014.933685
- McAninch EA, Fonseca TL, Poggioli R, et al. Epicardial adipose tissue has a unique transcriptome modified in severe coronary artery disease. Obesity (Silver Spring) 2015;23:1267-78. https://doi.org/10.1002/oby.21059
- Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc 2014;3:e000582.
- Mazurek T, Kiliszek M, Kobylecka M, et al. Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am J Cardiol 2014;113:1505-8. https://doi.org/10.1016/j.amjcard.2014.02.005
- Mazurek T, Zhang L, Zalewski A, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-6. https://doi.org/10.1161/01.CIR.0000099542.57313.C5
- Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817-20. https://doi.org/10.1016/S0140-6736(05)66585-3
- Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22:450-7. https://doi.org/10.1016/j.tem.2011.07.003
- Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009;10:269-79. https://doi.org/10.1111/j.1467-789X.2009.00571.x
- Woodward L, Akoumianakis I, Antoniades C. Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol 2016 [Epub ahead of print].
- Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005;97:1245-52. https://doi.org/10.1161/01.RES.0000194328.57164.36
- Ouedraogo R, Gong Y, Berzins B, et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007;117:1718-26. https://doi.org/10.1172/JCI29623
- Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-31.
- Antonopoulos AS, Margaritis M, Coutinho P, et al. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular adipose tissue. Diabetes 2015;64:2207-19. https://doi.org/10.2337/db14-1011
-
Antonopoulos AS, Margaritis M, Verheule S, et al. Mutual regulation of epicardial adipose tissue and myocardial redox state by
$PPAR-{\gamma}$ /adiponectin signalling. Circ Res 2016;118:842-55. https://doi.org/10.1161/CIRCRESAHA.115.307856 - Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005;11:1096-103. https://doi.org/10.1038/nm1295
- Essick EE, Wilson RM, Pimentel DR, et al. Adiponectin modulates oxidative stress-induced autophagy in cardiomyocytes. PLoS One 2013;8:e68697. https://doi.org/10.1371/journal.pone.0068697
- Joki Y, Ohashi K, Yuasa D, et al. FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun 2015;459:124-30. https://doi.org/10.1016/j.bbrc.2015.02.081
- Antonopoulos AS, Margaritis M, Coutinho P, et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 2014;34:2151-9. https://doi.org/10.1161/ATVBAHA.114.303828
- Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000;62:413-37. https://doi.org/10.1146/annurev.physiol.62.1.413
- Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010;7:22-9. https://doi.org/10.1038/nrcardio.2009.224
- Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008;117:3238-49. https://doi.org/10.1161/CIRCULATIONAHA.107.741645
- Tumer N, Erdos B, Matheny M, Cudykier I, Scarpace PJ. Leptin antagonist reverses hypertension caused by leptin overexpression, but fails to normalize obesity-related hypertension. J Hypertens 2007;25:2471-8. https://doi.org/10.1097/HJH.0b013e3282e9a9fd
- Zuo G, Du X, Zheng L, Wang C, Wang K, Li Y. The role of leptin in the ventricular remodeling process and its mechanism. Int J Clin Exp Med 2015;8:5553-8.
- Martinez-Martinez E, Jurado-Lopez R, Valero-Munoz M, et al. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J Hypertens 2014;32:1104-14. https://doi.org/10.1097/HJH.0000000000000149
-
Yan W, Zhang H, Liu P, et al. Impaired mitochondrial biogenesis due to dysfunctional adiponectin-AMPK-PGC-
$1{\alpha}$ signaling contributing to increased vulnerability in diabetic heart. Basic Res Cardiol 2013;108:329. https://doi.org/10.1007/s00395-013-0329-1 - Smith CC, Mocanu MM, Davidson SM, Wynne AM, Simpkin JC, Yellon DM. Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects. Br J Pharmacol 2006;149:5-13. https://doi.org/10.1038/sj.bjp.0706834
- Lee S, Lee HC, Kwon YW, et al. Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 2014;19:484-97. https://doi.org/10.1016/j.cmet.2014.01.013
- Langheim S, Dreas L, Veschini L, et al. Increased expression and secretion of resistin in epicardial adipose tissue of patients with acute coronary syndrome. Am J Physiol Heart Circ Physiol 2010;298:H746-53. https://doi.org/10.1152/ajpheart.00617.2009
- Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006;69:76-85. https://doi.org/10.1016/j.cardiores.2005.09.015
- Muse ED, Feldman DI, Blaha MJ, et al. The association of resistin with cardiovascular disease in the Multi-ethnic Study of Atherosclerosis. Atherosclerosis 2015;239:101-8. https://doi.org/10.1016/j.atherosclerosis.2014.12.044
- He Y, Bai XJ, Li FX, et al. Resistin may be an independent predictor of subclinical atherosclerosis formale smokers. Biomarkers 2017;22:291 -5. https://doi.org/10.1080/1354750X.2016.1252953
- Gencer B, Auer R, de Rekeneire N, et al. Association between resistin levels and cardiovascular disease events in older adults: the health, aging and body composition study. Atherosclerosis 2016;245:181-6. https://doi.org/10.1016/j.atherosclerosis.2015.12.004
- Kang S, Chemaly ER, Hajjar RJ, Lebeche D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem 2011;286:18465-73. https://doi.org/10.1074/jbc.M110.200022
- Rothwell SE, Richards AM, Pemberton CJ. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006;349:400-7. https://doi.org/10.1016/j.bbrc.2006.08.052
- Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011;51:144-55. https://doi.org/10.1016/j.yjmcc.2011.04.006
- Laurikka A, Vuolteenaho K, Toikkanen V, et al. Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur J Cardiothorac Surg 2014;46:729-36. https://doi.org/10.1093/ejcts/ezt634
- Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure--a novel link between metabolic signals and heart failure. Circ J 2007;71:460-4. https://doi.org/10.1253/circj.71.460
- Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010;20:143-8. https://doi.org/10.1016/j.tcm.2010.12.002
- Kazama K, Okada M, Yamawaki H. A novel adipocytokine, omentin, inhibits platelet-derived growth factor-BB-induced vascular smooth muscle cell migration through antioxidative mechanism. Am J Physiol Heart Circ Physiol 2014;306:H1714-9. https://doi.org/10.1152/ajpheart.00048.2014
- Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011;408:339-43. https://doi.org/10.1016/j.bbrc.2011.04.039
- Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014;25:348-55. https://doi.org/10.1016/j.tem.2014.03.009
- Uemura Y, Shibata R, Kanemura N, et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury. FASEB J 2015;29:141-51. https://doi.org/10.1096/fj.14-258129
- Kazama K, Okada M, Yamawaki H. Adipocytokine, omentin inhibits doxorubicin-induced H9c2 cardiomyoblasts apoptosis through the inhibition of mitochondrial reactive oxygen species. Biochem Biophys Res Commun 2015;457:602-7. https://doi.org/10.1016/j.bbrc.2015.01.032
- Kataoka Y, Shibata R, Ohashi K, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol 2014;63:2722-33. https://doi.org/10.1016/j.jacc.2014.03.032
- Harada K, Shibata R, Ouchi N, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis 2016;251:299-304. https://doi.org/10.1016/j.atherosclerosis.2016.07.003
- Saely CH, Leiherer A, Muendlein A, et al. High plasma omentin predicts cardiovascular events independently from the presence and extent of angiographically determined atherosclerosis. Atherosclerosis 2016;244:38-43. https://doi.org/10.1016/j.atherosclerosis.2015.10.100
- Narumi T, Watanabe T, Kadowaki S, et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol 2014;13:84. https://doi.org/10.1186/1475-2840-13-84
- Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013;2013:946427.
- Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol 2009;77:1612-20. https://doi.org/10.1016/j.bcp.2009.02.017
- Vallejo S, Romacho T, Angulo J, et al. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 2011;6:e27299. https://doi.org/10.1371/journal.pone.0027299
- Li B, Zhao Y, Liu H, et al. Visfatin destabilizes atherosclerotic plaques in apolipoprotein E-deficient mice. PLoS One 2016;11:e0148273. https://doi.org/10.1371/journal.pone.0148273
- Lovren F, Pan Y, Shukla PC, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009;296:E1440-9. https://doi.org/10.1152/ajpendo.90780.2008
- Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009;383:503-8. https://doi.org/10.1016/j.bbrc.2009.04.074
- Xiao J, Sun B, Li M, Wu Y, Sun XB. A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease. J Cell Physiol 2013;228:495-501. https://doi.org/10.1002/jcp.24257
- Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med 2008;12:1395-403. https://doi.org/10.1111/j.1582-4934.2008.00332.x
- Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011;27:515-27. https://doi.org/10.1002/dmrr.1201
- Vanhoutte PM. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ J 2009;73:595-601. https://doi.org/10.1253/circj.CJ-08-1169
- Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007;115:972-80. https://doi.org/10.1161/CIRCULATIONAHA.106.665893
- Hung WC, Yu TH, Hsu CC, et al. Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction. Clin Invest Med 2015;38:E100-9. https://doi.org/10.25011/cim.v38i3.22705
- McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol 2009;6:410-7. https://doi.org/10.1038/nrcardio.2009.57
- Hartman J, Frishman WH. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev 2014;22:147-51. https://doi.org/10.1097/CRD.0000000000000021
- Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013;227:216-21. https://doi.org/10.1016/j.atherosclerosis.2012.12.029
-
Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte
$NF-{\kappa}B$ p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res 2011;89:129-38. https://doi.org/10.1093/cvr/cvq274 - Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115:1398-407. https://doi.org/10.1161/CIRCULATIONAHA.106.643585
- Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53. https://doi.org/10.1161/01.RES.0000130526.20854.fa
- Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7. https://doi.org/10.1161/01.CIR.0000037521.71373.44
- Wong M, Oakley SP, Young L, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1277-84. https://doi.org/10.1136/ard.2007.086157
- Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011;38:2169-71. https://doi.org/10.3899/jrheum.110340
- Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2011;8:13-21.
- Marcus Y, Shefer G, Stern N. Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2013;378:1-14. https://doi.org/10.1016/j.mce.2012.06.021
- Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The Renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflamm 2014;2014:689360.
- Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:H2009-23. https://doi.org/10.1152/ajpheart.00522.2007
- Ellmers LJ, Rademaker MT, Charles CJ, Yandle TG, Richards AM. (Pro)renin receptor blockade ameliorates cardiac injury and remodeling and improves function after myocardial infarction. J Card Fail 2016;22:64-72. https://doi.org/10.1016/j.cardfail.2015.08.341
- Nguyen Dinh Cat A, Antunes TT, Callera GE, et al. Adipocyte-specific mineralocorticoid receptor overexpression in mice is associated with metabolic syndrome and vascular dysfunction: role of redox-sensitive PKG-1 and Rho kinase. Diabetes 2016;65:2392-403. https://doi.org/10.2337/db15-1627
- von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 2013;27:171-9. https://doi.org/10.1007/s10557-012-6424-y
- Venteclef N, Guglielmi V, Balse E, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2015;36:795-805a. https://doi.org/10.1093/eurheartj/eht099
- Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014;102:205-13. https://doi.org/10.1093/cvr/cvu045
- Thanassoulis G, Massaro JM, O'Donnell CJ, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 2010;3:345-50. https://doi.org/10.1161/CIRCEP.109.912055
- Reilly SN, Jayaram R, Nahar K, et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011;124:1107-17. https://doi.org/10.1161/CIRCULATIONAHA.111.029223
Cited by
- Macrophage MicroRNAs as Therapeutic Targets for Atherosclerosis, Metabolic Syndrome, and Cancer vol.19, pp.6, 2017, https://doi.org/10.3390/ijms19061756
- Perivascular adipose tissue and coronary atherosclerosis vol.104, pp.20, 2017, https://doi.org/10.1136/heartjnl-2017-312324
- The role of perivascular adipose tissue in the development of cardiovascular diseases. The importance of diagnosis for assessing the risk stratification of cardiovascular diseases vol.91, pp.4, 2017, https://doi.org/10.26442/00403660.2019.04.000186
- The role of obesity in the development of atrial fibrillation: current problem status vol.18, pp.4, 2017, https://doi.org/10.15829/1728-8800-2019-4-109-114
- Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality vol.22, pp.1, 2017, https://doi.org/10.3892/mmr.2020.11127
- Plasticizers and Cardiovascular Health: Role of Adipose Tissue Dysfunction vol.11, pp.None, 2021, https://doi.org/10.3389/fphar.2020.626448